Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 245 entries
Sorted by: Best Match Show Resources per page
[In Process Citation].

Orvosi hetilap

Horváth G, Gerlei Z, Gervain J, Lengyel G, Makara M, Pár A, Rókusz L, Szalay F, Tornai I, Werling K, Hunyady B.
PMID: 26667112
Orv Hetil. 2015 Dec 15;156:25-36. doi: 10.1556/OH.2015.30331.

Diagnosis and treatment of HBV/HDV infection means for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while society benefits from eliminating the chances of further...

Cite
Horváth G, Gerlei Z, Gervain J, et al. A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től. [In Process Citation]. Orv Hetil. 2015;156:25-36doi: 10.1556/OH.2015.30331.
Horváth, G., Gerlei, Z., Gervain, J., Lengyel, G., Makara, M., Pár, A., Rókusz, L., Szalay, F., Tornai, I., Werling, K., & Hunyady, B. (2015). A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től. [In Process Citation]. Orvosi hetilap, 15625-36. https://doi.org/10.1556/OH.2015.30331
Horváth, Gábor, et al. "A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től." [In Process Citation]. Orvosi hetilap vol. 156 (2015): 25-36. doi: https://doi.org/10.1556/OH.2015.30331
Horváth G, Gerlei Z, Gervain J, Lengyel G, Makara M, Pár A, Rókusz L, Szalay F, Tornai I, Werling K, Hunyady B. A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től. [In Process Citation]. Orv Hetil. 2015 Dec 15;156:25-36. doi: 10.1556/OH.2015.30331. Hungarian. PMID: 26667112.
Copy Download .nbib Format: NLM
Neutrophil gelatinase-associated lipocalin accurately predicts renal tubular injury in patients with chronic hepatitis B treated with nucleos(t)ide analogs.

Hepatology research : the official journal of the Japan Society of Hepatology

Zhang Y, Li J, Li F, Qi X, Zhang J.
PMID: 28452097
Hepatol Res. 2018 Feb;48(2):144-152. doi: 10.1111/hepr.12908. Epub 2017 Jun 29.

AIM: Little is known about the impact of long-term use of nucleos(t)ide analogs on tubular function in patients with chronic hepatitis B. Previous studies showed that neutrophil gelatinase-associated lipocalin (NGAL) elevation was associated with renal tubular injury. We evaluated...

Cite
Zhang Y, Li J, Li F, et al. Neutrophil gelatinase-associated lipocalin accurately predicts renal tubular injury in patients with chronic hepatitis B treated with nucleos(t)ide analogs. Hepatol Res. 2017;48(2):144-152doi: 10.1111/hepr.12908.
Zhang, Y., Li, J., Li, F., Qi, X., & Zhang, J. (2018). Neutrophil gelatinase-associated lipocalin accurately predicts renal tubular injury in patients with chronic hepatitis B treated with nucleos(t)ide analogs. Hepatology research : the official journal of the Japan Society of Hepatology, 48(2), 144-152. https://doi.org/10.1111/hepr.12908
Zhang, Yao, et al. "Neutrophil gelatinase-associated lipocalin accurately predicts renal tubular injury in patients with chronic hepatitis B treated with nucleos(t)ide analogs." Hepatology research : the official journal of the Japan Society of Hepatology vol. 48,2 (2018): 144-152. doi: https://doi.org/10.1111/hepr.12908
Zhang Y, Li J, Li F, Qi X, Zhang J. Neutrophil gelatinase-associated lipocalin accurately predicts renal tubular injury in patients with chronic hepatitis B treated with nucleos(t)ide analogs. Hepatol Res. 2018 Feb;48(2):144-152. doi: 10.1111/hepr.12908. Epub 2017 Jun 29. PMID: 28452097.
Copy Download .nbib Format: NLM
A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients.

Hepatology international

Chen CH, Hu TH, Hung CH, Lu SN, Wang JH, Chang MH, Changchien CS, Lee CM.
PMID: 26201920
Hepatol Int. 2013 Jul;7(3):832-43. doi: 10.1007/s12072-013-9440-5. Epub 2013 Jul 31.

PURPOSE: To compare the efficacy of entecavir (ETV) monotherapy up to 4 years in nucleos(t)ide analog (NA)-experienced and -naïve subjects.METHODS: One hundred sixty NA-experienced and 282 naïve chronic hepatitis B patients who were treated with ETV were enrolled. Of...

Cite
Chen CH, Hu TH, Hung CH, et al. A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients. Hepatol Int. 2013;7(3):832-43doi: 10.1007/s12072-013-9440-5.
Chen, C. H., Hu, T. H., Hung, C. H., Lu, S. N., Wang, J. H., Chang, M. H., Changchien, C. S., & Lee, C. M. (2013). A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients. Hepatology international, 7(3), 832-43. https://doi.org/10.1007/s12072-013-9440-5
Chen, Chien-Hung, et al. "A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients." Hepatology international vol. 7,3 (2013): 832-43. doi: https://doi.org/10.1007/s12072-013-9440-5
Chen CH, Hu TH, Hung CH, Lu SN, Wang JH, Chang MH, Changchien CS, Lee CM. A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients. Hepatol Int. 2013 Jul;7(3):832-43. doi: 10.1007/s12072-013-9440-5. Epub 2013 Jul 31. PMID: 26201920.
Copy Download .nbib Format: NLM
Modeling and simulating dynamics of complete- and poor-response chronic hepatitis B chinese patients for adefovir and traditional chinese medicine plus adefovir therapy.

Evidence-based complementary and alternative medicine : eCAM

Min L, Chen X, Ye Y, Zhang Q, Ru S, Li X.
PMID: 24282437
Evid Based Complement Alternat Med. 2013;2013:767290. doi: 10.1155/2013/767290. Epub 2013 Nov 06.

ChiCTR-TRC-11001263 study was the first large-scale double-blind randomized placebo-controlled traditional Chinese medicines (TCMs) and adefovir (ADV) antihepatitis B virus (HBV) infection trial in the world. A total of 560 hepatitis B e antigen- (HBeAg-) positive Chinese patients with chronical...

Cite
Min L, Chen X, Ye Y, et al. Modeling and simulating dynamics of complete- and poor-response chronic hepatitis B chinese patients for adefovir and traditional chinese medicine plus adefovir therapy. Evid Based Complement Alternat Med. 2013;2013:767290doi: 10.1155/2013/767290.
Min, L., Chen, X., Ye, Y., Zhang, Q., Ru, S., & Li, X. (2013). Modeling and simulating dynamics of complete- and poor-response chronic hepatitis B chinese patients for adefovir and traditional chinese medicine plus adefovir therapy. Evidence-based complementary and alternative medicine : eCAM, 2013767290. https://doi.org/10.1155/2013/767290
Min, Lequan, et al. "Modeling and simulating dynamics of complete- and poor-response chronic hepatitis B chinese patients for adefovir and traditional chinese medicine plus adefovir therapy." Evidence-based complementary and alternative medicine : eCAM vol. 2013 (2013): 767290. doi: https://doi.org/10.1155/2013/767290
Min L, Chen X, Ye Y, Zhang Q, Ru S, Li X. Modeling and simulating dynamics of complete- and poor-response chronic hepatitis B chinese patients for adefovir and traditional chinese medicine plus adefovir therapy. Evid Based Complement Alternat Med. 2013;2013:767290. doi: 10.1155/2013/767290. Epub 2013 Nov 06. PMID: 24282437; PMCID: PMC3825269.
Copy Download .nbib Format: NLM
Dynamic Changes of Treg and Th17 Cells and Related Cytokines Closely Correlate With the Virological and Biochemical Response in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogues Treatment.

Hepatitis monthly

Yu XP, Guo RY, Su ML, Ming DS, Lin CZ, Deng Y, Lin ZZ, Su ZJ.
PMID: 24403916
Hepat Mon. 2013 Dec 23;13(12):e15332. doi: 10.5812/hepatmon.15332. eCollection 2013.

BACKGROUND: The restoration of HBV-specific T-cell response during antiviral therapy is associated with CD4+T-cell activity. Treg cells and Th17 cells are subtypes of CD4+T cell. However, it has remained unknown how the Treg and Th17 cells and their associated...

Cite
Yu XP, Guo RY, Su ML, et al. Dynamic Changes of Treg and Th17 Cells and Related Cytokines Closely Correlate With the Virological and Biochemical Response in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogues Treatment. Hepat Mon. 2013;13(12):e15332doi: 10.5812/hepatmon.15332.
Yu, X. P., Guo, R. Y., Su, M. L., Ming, D. S., Lin, C. Z., Deng, Y., Lin, Z. Z., & Su, Z. J. (2013). Dynamic Changes of Treg and Th17 Cells and Related Cytokines Closely Correlate With the Virological and Biochemical Response in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogues Treatment. Hepatitis monthly, 13(12), e15332. https://doi.org/10.5812/hepatmon.15332
Yu, Xue-Ping, et al. "Dynamic Changes of Treg and Th17 Cells and Related Cytokines Closely Correlate With the Virological and Biochemical Response in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogues Treatment." Hepatitis monthly vol. 13,12 (2013): e15332. doi: https://doi.org/10.5812/hepatmon.15332
Yu XP, Guo RY, Su ML, Ming DS, Lin CZ, Deng Y, Lin ZZ, Su ZJ. Dynamic Changes of Treg and Th17 Cells and Related Cytokines Closely Correlate With the Virological and Biochemical Response in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogues Treatment. Hepat Mon. 2013 Dec 23;13(12):e15332. doi: 10.5812/hepatmon.15332. eCollection 2013. PMID: 24403916; PMCID: PMC3877654.
Copy Download .nbib Format: NLM
Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B.

Experimental and therapeutic medicine

Wang Y, Liu S, Chen YU, Zheng S, Zhou LI, Lu F, Duan Z.
PMID: 27313669
Exp Ther Med. 2016 Jun;11(6):2293-2299. doi: 10.3892/etm.2016.3230. Epub 2016 Apr 06.

Adefovir (ADV) sequential monotherapy was included in the 2005 Asia-Pacific guidelines for the management of patients with lamivudine (LAM) resistance. However, following the development of ADV resistance, the proportion of resistant variants during combined rescue therapy with ADV and...

Cite
Wang Y, Liu S, Chen YU, et al. Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. Exp Ther Med. 2016;11(6):2293-2299doi: 10.3892/etm.2016.3230.
Wang, Y., Liu, S., Chen, Y. U., Zheng, S., Zhou, L. I., Lu, F., & Duan, Z. (2016). Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. Experimental and therapeutic medicine, 11(6), 2293-2299. https://doi.org/10.3892/etm.2016.3230
Wang, Yang, et al. "Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B." Experimental and therapeutic medicine vol. 11,6 (2016): 2293-2299. doi: https://doi.org/10.3892/etm.2016.3230
Wang Y, Liu S, Chen YU, Zheng S, Zhou LI, Lu F, Duan Z. Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. Exp Ther Med. 2016 Jun;11(6):2293-2299. doi: 10.3892/etm.2016.3230. Epub 2016 Apr 06. PMID: 27313669; PMCID: PMC4888018.
Copy Download .nbib Format: NLM
Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.

World journal of virology

Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW.
PMID: 24175223
World J Virol. 2012 Dec 12;1(6):174-83. doi: 10.5501/wjv.v1.i6.174.

Antiviral treatment is the only option to prevent or defer the occurrence of hepatocellular carcinoma (HCC) in patients chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV). The approved medication for the treatment of chronic HBV...

Cite
Chen LP, Zhao J, Du Y, et al. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol. 2012;1(6):174-83doi: 10.5501/wjv.v1.i6.174.
Chen, L. P., Zhao, J., Du, Y., Han, Y. F., Su, T., Zhang, H. W., & Cao, G. W. (2012). Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World journal of virology, 1(6), 174-83. https://doi.org/10.5501/wjv.v1.i6.174
Chen, Li-Ping, et al. "Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma." World journal of virology vol. 1,6 (2012): 174-83. doi: https://doi.org/10.5501/wjv.v1.i6.174
Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol. 2012 Dec 12;1(6):174-83. doi: 10.5501/wjv.v1.i6.174. PMID: 24175223; PMCID: PMC3782279.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 15148527
Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity(R), the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004;26(3):211-44
Bayés, M., Rabasseda, X., & Prous, J. R. (2004). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 26(3), 211-44.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 26,3 (2004): 211-44.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44. PMID: 15148527.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 18985183
Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008;30(7):543-88
Tomillero, A., & Moral, M. A. (2008). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 30(7), 543-88.
Tomillero, A, and Moral, M A. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 30,7 (2008): 543-88.
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88. PMID: 18985183.
Copy Download .nbib Format: NLM
Viral hepatitis.

Current opinion in infectious diseases

Trépo C, Zoulim F, Pradat P.
PMID: 17035815
Curr Opin Infect Dis. 1999 Oct;12(5):481-90. doi: 10.1097/00001432-199910000-00011.

Hepatitis A is still the most frequently reported vaccine preventable disease. A reduction in the incidence will only be achieved by routine childhood vaccination rather than by targeted vaccination of high-risk groups. A larger vaccine program is warranted. Hepatitis...

Cite
Trépo C, Zoulim F, Pradat P. Viral hepatitis. Curr Opin Infect Dis. 1999;12(5):481-90doi: 10.1097/00001432-199910000-00011.
Trépo, C., Zoulim, F., & Pradat, P. (1999). Viral hepatitis. Current opinion in infectious diseases, 12(5), 481-90. https://doi.org/10.1097/00001432-199910000-00011
Trépo, C, et al. "Viral hepatitis." Current opinion in infectious diseases vol. 12,5 (1999): 481-90. doi: https://doi.org/10.1097/00001432-199910000-00011
Trépo C, Zoulim F, Pradat P. Viral hepatitis. Curr Opin Infect Dis. 1999 Oct;12(5):481-90. doi: 10.1097/00001432-199910000-00011. PMID: 17035815.
Copy Download .nbib Format: NLM
Advances in Molecular Diagnosis of HBV Infection and Drug Resistance.

International journal of medical sciences

Sablon E, Shapiro F.
PMID: 15968334
Int J Med Sci. 2005;2(1):8-16. doi: 10.7150/ijms.2.8. Epub 2005 Jan 05.

Serological markers are key elements in diagnosing acute hepatitis B virus (HBV) infection and determining its possible evolution towards chronicity. Once treatment of chronic HBV is initiated with approved anti-hepadnaviral agents, such as lamivudine, interferon-alpha, or adefovir dipivoxil, the...

Cite
Sablon E, Shapiro F. Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int J Med Sci. 2005;2(1):8-16doi: 10.7150/ijms.2.8.
Sablon, E., & Shapiro, F. (2005). Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. International journal of medical sciences, 2(1), 8-16. https://doi.org/10.7150/ijms.2.8
Sablon, Erwin, and Shapiro, Fred. "Advances in Molecular Diagnosis of HBV Infection and Drug Resistance." International journal of medical sciences vol. 2,1 (2005): 8-16. doi: https://doi.org/10.7150/ijms.2.8
Sablon E, Shapiro F. Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int J Med Sci. 2005;2(1):8-16. doi: 10.7150/ijms.2.8. Epub 2005 Jan 05. PMID: 15968334; PMCID: PMC1142219.
Copy Download .nbib Format: NLM
Colloid probe AFM investigation of interactions between fibrinogen and PEG-like plasma polymer surfaces.

Langmuir : the ACS journal of surfaces and colloids

Bremmell KE, Kingshott P, Ademovic Z, Winther-Jensen B, Griesser HJ.
PMID: 16378437
Langmuir. 2006 Jan 03;22(1):313-8. doi: 10.1021/la052143a.

Interaction forces between surfaces designed to be protein resistant and fibrinogen (Fg) were investigated in phosphate-buffered saline with colloid probe atomic force microscopy. The surfaces of the silica probes were coated with a layer of fibrinogen molecules by adsorption...

Cite
Bremmell KE, Kingshott P, Ademovic Z, et al. Colloid probe AFM investigation of interactions between fibrinogen and PEG-like plasma polymer surfaces. Langmuir. 2006;22(1):313-8doi: 10.1021/la052143a.
Bremmell, K. E., Kingshott, P., Ademovic, Z., Winther-Jensen, B., & Griesser, H. J. (2006). Colloid probe AFM investigation of interactions between fibrinogen and PEG-like plasma polymer surfaces. Langmuir : the ACS journal of surfaces and colloids, 22(1), 313-8. https://doi.org/10.1021/la052143a
Bremmell, Kristen E, et al. "Colloid probe AFM investigation of interactions between fibrinogen and PEG-like plasma polymer surfaces." Langmuir : the ACS journal of surfaces and colloids vol. 22,1 (2006): 313-8. doi: https://doi.org/10.1021/la052143a
Bremmell KE, Kingshott P, Ademovic Z, Winther-Jensen B, Griesser HJ. Colloid probe AFM investigation of interactions between fibrinogen and PEG-like plasma polymer surfaces. Langmuir. 2006 Jan 03;22(1):313-8. doi: 10.1021/la052143a. PMID: 16378437.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 245 entries